SANDU PHARMACEUTICALS LTD.

Sandu Pharmaceuticals Ltd has announced that its Board of Directors will convene on August 11, 2026, to consider and approve the standalone unaudited financial results for the quarter ended June 30, 2026. The meeting is scheduled for 4:00 p.m. at the company's corporate office in Chembur, Mumbai. Additionally, the board will discuss any other matters with the Chair's permission. The company has also informed that the trading window for its directors and designated employees will remain closed from July 1, 2026, until 48 hours after the financial results announcement.

Sandu Pharmaceuticals Ltd announced significant board changes following the demise of Managing Director Shri Umesh B. Sandu. Dr. Neeti Madan Kapre has been appointed as an Additional Non-Executive Independent Director for a five-year term. Concurrently, Shri Balram Viswanathan has been redesignated from Chairman and Non-Executive Independent Director to Chairman and Managing Director for three years, subject to member approval. The board also approved the reconstitution of key committees including Audit, Nomination and Remuneration, and Stakeholders' Relationship.

Sandu Pharmaceuticals Ltd held a Board of Directors meeting on July 11, 2026. The board noted the demise of Managing Director Shri Umesh B. Sandu. Dr. Neeti Madan Kapre was appointed as an Additional Non-Executive Independent Director for a five-year term. Shri Balram Viswanathan was redesignated from Chairman and Non-Executive Independent Director to Chairman and Managing Director for three years, subject to member approval. Consequently, the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee were reconstituted.

Sandu Pharmaceuticals Ltd held a Board Meeting on July 11, 2026. The Board noted the demise of Managing Director, Shri Umesh B. Sandu, who passed away on June 19, 2026. Dr. Neeti Madan Kapre was appointed as an Additional Non-Executive Independent Director for a five-year term. Shri Balram Viswanathan was redesignated from Chairman and Non-Executive Independent Director to Chairman and Managing Director for three years, subject to member approval. The Board also approved the reconstitution of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee.

Sandu Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for July 11, 2026. The meeting agenda includes placing on record the demise of Managing Director Shri Umesh B. Sandu, appointing a new Managing Director, reconstituting Board Committees, and appointing an Additional Independent Director. The trading window for company directors and designated employees will be closed from July 1, 2026, until 48 hours after the announcement of financial results for the quarter ended June 30, 2026.

Sandu Pharmaceuticals Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with SEBI regulations and the company's 'Code of Conduct for Prevention of Insider Trading'. The trading window will be shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. This restriction applies to Directors, KMPs, Promoters, Promoter Group, Designated Persons, and their immediate relatives. The date for the Board Meeting to consider these financial results will be intimated separately.

Sandu Pharmaceuticals Ltd announced the demise of its Managing Director and Promoter, Shri Umesh Sandu (DIN:01132141), on June 19, 2026. The company stated that his vision and participation were invaluable. Consequently, he ceases to be a member of the Audit Committee and Stakeholders Relationship Committee. The company expressed that his sudden demise is an irreparable loss and conveyed condolences to his family. The disclosure was made pursuant to SEBI Listing Regulations.

Sandu Pharmaceuticals Ltd announced the sad demise of its Promoter and Managing Director, Shri Umesh Sandu (DIN:01132141), on June 19, 2026. His passing is considered an irreparable loss to the company, which benefited greatly from his vision and active participation. Consequently, he ceases to be a member of the Audit Committee and Stakeholders Relationship Committee. The company's Chairman, directors, and employees have conveyed their deepest condolences to his family.

Sandu Pharmaceuticals Ltd announced the sad demise of its Managing Director, Shri Umesh Sandu (DIN:01132141), on June 19, 2026. He was also a promoter of the company. His leadership and vision were instrumental in the company's growth. Consequently, he ceases to be a member of the Audit Committee and Stakeholders Relationship Committee. The company and its employees have expressed deep condolences to his family, recognizing his passing as an irreparable loss.

Sandu Pharmaceuticals Ltd received a demand order from the Assistant Commissioner due to discrepancies between invoice quantity and physical verification of goods in Uttar Pradesh. The company accepted the liability and paid a penalty of ₹31,699 on May 6, 2026. Consequently, the GST authority dropped the proceedings, and the company anticipates no major impact.